Clinical trials: Etanercept
Plaque Psoriasis.
ASIS for Enbrel in Plaque Psoriasis
AUTOMATIC SUBDERMAL INJECTOR SYSTEM (ASIS) Corporation has developed and patented the only automatic injection system for delivery of injectable products to the optimum spot, just outside of the fascia, which exists subdermally…
- Trial name
- ASISinPP (NCT02112097)
- Testing
- Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- ASIS Corporation
Healthy
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects
The purpose of this study is to compare the pharmacokinetics, safety and immunogenicity of SB4 and Enbrel (EU sourced Enbrel and US sourced Enbrel) in healthy male subjects.
- Trial name
- NCT01865552
- Testing
- SB4, EU sourced Enbrel, US sourced Enbrel
- Where
- Germany
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Samsung Bioepis Co., Ltd.
Rheumatoid Arthritis (RA)
Niclosamide With Etanercept in Rheumatoid Arthritis
Assessment of the adjuvant use Niclosamide With Etanercept in Rheumatoid Arthritis
- Trial name
- NCT03160001
- Testing
- Niclosamide, Etanercept
- Where
- Iraq
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Faiq Gorial
Ankylosing Spondylitis
An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
The primary objective of this study was to determine the long-term safety of etanercept in adults with AS who had completed study 0881A3-311-EU.
- Trial name
- NCT00421980
- Testing
- Etanercept
- Where
- Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriasis, Atopic Dermatitis
Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents
Psoriasis is a common inflammatory disease of the skin and joints with a prevalence of 1-3% in the caucasian population of Northern Europe and the US.
- Conditions
- Psoriasis, Atopic Dermatitis, Atherosclerosis
- Trial name
- NCT01356758
- Testing
- biological treatment
- Where
- Denmark
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Healthy
Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®
To compare the pharmacokinetic characteristic of LBEC0101 25mg with the active comparator, Enbrel® 25 mg.
- Trial name
- NCT01145950
- Testing
- LBEC0101, Enbrel
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Polymyalgia Rheumatica
Etanercept Treatment in the Early Course of Polymyalgia Rheumatica
The purpose of this study is to evaluate the effect of the tumor necrosis factor alpha (TNF) antagonist, etanercept, on the early clinical course of polymyalgia rheumatica (PMR).
- Trial name
- NCT00524381
- Testing
- Etanercept (Enbrel)
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Psoriasis
Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study
The main aims of this study are to determine whether: a) psoriasis patients with or without arthritis have more cardiovascular inflammation than healthy subjects and b)3 months of etanercept (enbrel) therapy (prescribed to…
- Trial name
- MMAPPS (NCT01522742)
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Plaque Psoriasis
The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab
To describe the response of etanercept after adalimumab has failed to produce a satisfactory response in moderate to severe plaque psoriasis.
- Trial name
- NCT00833729
- Testing
- etanercept
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Dermatrials Research
Healthy
Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers
The purpose of this study is to compare the safety and pharmacokinetic characteristics of HD203 liquid with those of etanercept (enbrel) prefilled injection after subcutaneous injection
- Trial name
- NCT01894412
- Testing
- Etanercept (Enbrel), HD203
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hanwha Chemical
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
This is a prospective, multicenter cohort observational; study to compare treatment outcomes in patients admitted to the hospital with Stevens-Johnsons Syndrome/Toxic Epidermolysis, aiming to assess the utility of medical…
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Reaction
- Trial name
- NCT03585946
- Testing
- Site specific standard of care comparison
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Ulcerative Colitis
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
The primary goal of the study is to develop an early (within 4 weeks) combined microbiota/metabolic signature predicting clinical response upon anti-inflammatory treatment in UC patients.
- Trial name
- COMMIT (NCT05702879)
- Testing
- Ozanimod, TNF Inhibitor, Steroids
- Where
- Switzerland
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA
Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls
This study is designed to establish the prevalence of anal squamous intraepithelial lesion (ASIL) in patients with inflammatory bowel disease (IBD) and healthy controls.
- Trial name
- ADIBD (NCT01860963)
- Testing
- Anal Pap smear and HPV DNA testing
- Where
- United States
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Stanford University
Psoriasis
Regulatory T-cells in Psoriasis Patients as Targets for Therapy
The aim of this study is to understand which therapies will suppress effector cells and promote regulatory T cells and To test whether patients with a better response to therapy and longer psoriasis-free periods develop a higher…
- Trial name
- NCT01233583
- Testing
- Dovobet, neotigason, etanercept, adalimumab. infliximab
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Aberdeen
Psoriasis
Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
Psoriasis has been associated with an increasing risk for atherosclerosis. The investigators investigated whether surrogate markers of subclinical atherosclerosis, vascular dysfunction and myocardial dysfunction are impaired in…
- Trial name
- NCT02144857
- Testing
- etanercept, ustekinumab, cyclosporine
- Where
- Greece
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Athens
Healthy
A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
The primary purpose of this study is to assess the effect of nipocalimab on the pharmacokinetic (PK) of etanercept (Part 1); and to assess the effect of hydroxychloroquine (HCQ) on total serum immunoglobin G (IgG) reduction by…
- Trial name
- NCT04973566
- Testing
- Nipocalimab, Etanercept, Hydroxychloroquine
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers
The purpose of this study was to compare the safety and pharmacokinetic characteristics of DWP422 25 mg with those of ENBREL 25MG PFS INJ. after subcutaneous injection in healthy male volunteers.
- Trial name
- NCT01635686
- Testing
- DWP422 25mg, ENBREL 25MG PFS INJ.
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Juvenile Idiopathic Arthritis
Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis
This open labelled randomized controlled trial will be carried out at the University of Child Health and the Children's Hospital, Lahore consisting of 6 months .
- Trial name
- NCT07386587
- Testing
- Injection, Etanercept, 25 Mg (Code May Be Used for Medicare When Drug Administered Under the Direct Supervision of A Physician, Not for Use When Drug is Self Administered)
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Child Health Sciences and Children's Hospital, Lahore
Healthy
Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®
To compare the pharmacokinetic characteristic of LBEC0101 25mg with active comparator, Enbrel® 25mg.
- Trial name
- NCT01725620
- Testing
- LBEC0101 (Etanercept 25mg), Enbrel (Etanercept 25mg)
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Healthy
Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male Volunteers
The purpose of this study is compare the safety and pharmacokinetic characteristics of HD203 with those of etanercept after subcutaneous injection in healthy male volunteers.
- Trial name
- SPH (NCT01044836)
- Testing
- HD203
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hanwha Chemical